Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

New miR-155 target modulates cell migration and cytokine expression in DLBCL

Key clinical point: DEPTOR favors the migration of DLBCL cells and suppresses proinflammatory cytokines.

Major finding: miR-155 represses expression of DEPTOR and c-CBL in DLBCL cells.

Study details: Deptor expression and clinical parameters were studied in 76 newly diagnosed DLBCL patients.

Disclosures: The work was supported by the Foundation for Polish Science; there were no conflicts indicated by the authors.


“The role of microRNAs including miR-155 in the pathogenesis of lymphomas including the most common subtype diffuse large B-cell lymphoma (DLBCL) is unclear. Drs Jablonska et al investigated DLBCL cell lines and 76 primary samples from patients with newly diagnosed DLBCL and found that miR-155 has an impact on the B-cell receptor (BCR) pathway via DEPTOR (an mTOR phosphatase) and c-CBL (a SYK ubiquitin ligase). Their assays using ibrutinib, an inhibitor of the BCR pathway with efficacy in the non-germinal center subtype of DLBCL, provide additional data regarding a mechanism by which this drug may exert its effects and enhances understanding of the dysregulated BCR pathway in these DLBCL patients. While additional research is clearly needed to further elucidate the role of miR-155 in DLBCL, this research is promising and could have important clinical implications.”

Sarah Rutherford, MD

Assistant Professor of Medicine, Weill Cornell Medicine


Jabłońska E et al. Experimental Hematology. 2020;